Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?

about

Development of a reliable and accurate algorithm to quantify the tumor immune stroma (QTiS) across tumor types.

P2860

Q47554538-D53992F8-8132-4990-8E11-66F35AD21666

P2860

Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?

Item

http://www.wikidata.org/entity/Q54197932

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Optimal Scoring of Brightfield ...... ma: How Many Cells Are Enough?

@en

Optimal Scoring of Brightfield ...... ma: How Many Cells Are Enough?

@nl

type

Item

label

Optimal Scoring of Brightfield ...... ma: How Many Cells Are Enough?

@en

Optimal Scoring of Brightfield ...... ma: How Many Cells Are Enough?

@nl

prefLabel

Optimal Scoring of Brightfield ...... ma: How Many Cells Are Enough?

@en

Optimal Scoring of Brightfield ...... ma: How Many Cells Are Enough?

@nl

P1476

Optimal Scoring of Brightfield ...... ma: How Many Cells Are Enough?

@en

P2093

Fionnuala O'Connell

http://www.w3.org/2001/XMLSchema#string

Linda Feeley

http://www.w3.org/2001/XMLSchema#string

Mark A Corrigan

http://www.w3.org/2001/XMLSchema#string

Michael W Bennett

http://www.w3.org/2001/XMLSchema#string

Susan Prendeville

http://www.w3.org/2001/XMLSchema#string

Tara Jane Browne

http://www.w3.org/2001/XMLSchema#string

Vicki Livingstone

http://www.w3.org/2001/XMLSchema#string

P2860

The Measurement of Observer Agreement for Categorical Data

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid

Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens

Dual color chromogenic in situ hybridization for determination of HER2 status in breast cancer: a large comparative study to current state of the art fluorescence in situ hybridization.

HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.

Updated UK Recommendations for HER2 assessment in breast cancer.

P304

316-322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/AJCP/AQW017

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

145

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27124913

http://www.w3.org/2001/XMLSchema#string

Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?

about

P2860

P2860

Optimal Scoring of Brightfield Dual-Color In Situ Hybridization for Evaluation of HER2 Amplification in Breast Carcinoma: How Many Cells Are Enough?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698